Exchange: NASDAQ·Updated 07:58 PM EDT
AGEN logo

AGENAgenus Inc

$3.00
$0.04
(1.35%)
Today
Closed $3.00
$0.00
(0.00%)
After Hours
EarningsAug 10
Mkt Cap$124.93M
Vol868,396.00
News
all
press releases
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Zacks
News Placeholder
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
Zacks
News Placeholder
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.
Zacks
News Placeholder
Agenus Announces Virtual 2026 Annual Shareholders Meeting
Agenus Inc. (Agenus) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:45 a.m. ET. To participate in...
Business Wire
News Placeholder
IBRX Stock Outlook After Q1 Results and a New FDA Review
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
Zacks
News Placeholder
ImmunityBio: Anktiva Explained and What Comes Next
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.
Zacks
News Placeholder
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
Zacks
News Placeholder
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
Zacks
News Placeholder
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.